EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Spectral AI Inc. (MDAI) fair value: what the stock is really worth

We calculate from audited financials what Spectral AI Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 23, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US84757T1051

SA Spectral AI Inc. logo Thin data Jun 23, 2026

Spectral AI Inc.

MDAI · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value $1.84 · Undervalued (+13%)
!Quality 37/100
!Weak Growth (revenue 3y −8.2 %/yr)
!Loss-making · -65.5% net margin (TTM)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (1/7)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.43 $0.9400 Fair Value $1.84 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.

How to read this chart

60‑month range $0.9400 – $14.43 · fair‑value band $1.38 – $2.30 · the $1.62 price screens below the $1.84 fair value. Dashed = 300-day average. As of Jun 23, 2026.

Follow Spectral AI in your weekly email

Every Wednesday you see whether Spectral AI is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.

Show more

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient's wounds. Its system also develops AI-Burn software and MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images. Spectral AI, Inc. is headquartered in Dallas, Texas.

Stock analysis

Spectral AI Inc. (MDAI) currently trades at $1.62, while our model-based Fair Value estimate is $1.84, implying the stock looks roughly 11.8% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $1.38 (bear) to $2.30 (bull), the price of $1.62 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Spectral AI Inc. reported revenue of $19.7M in FY2025 versus $15.2M in FY2021, a compound +6.6%/yr. Reported net income was −$7.6M in FY2025.

Key figures

Market cap $52.0M · P/S ratio 3.24 · EPS (TTM) $−0.3200 · Net margin −38.5% · Return on equity −2,308% · Return on assets (EBIT) −50.5% · Operating margin −123% · Revenue (TTM) $15.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 40% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 13%, MDAI screens cheaper than that median.

Notify me when MDAI reaches fair value

Put MDAI on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 39 · Market factors (momentum, volatility) 24

Profitability 36
Margins and returns on capital today
Quality Growth 51
Are margins and returns improving?
Cashflow 39
Earnings quality: real cash, not paper profit
Fin. Strength 33
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 24
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−33.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−27.4% (2021) → −43.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch MDAI, get fair value alerts →

Compare Spectral AI Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside +13% · Top 25%
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −42% · Bottom 25%
Net margin (TTM) −66% · Bottom 25%
Operating margin (TTM) −123% · Bottom 25%
Growth and dividend
Revenue growth −30% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 3.38× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)51 · sector 10
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 40

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.07 $74.79 −26%
Medtronic plc MDT $89.30 $65.57 −27%
Stryker Corporation SYK $269.75 $296.73 +10%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Spectral AI Inc. Fair Value". https://www.fairvalue-calculator.com/stock/MDAI

Frequently asked questions

Is Spectral AI Inc. (MDAI) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of $1.84 versus a price of $1.62, about +13% upside (undervalued).
What is the fair value of MDAI?
Our model-based fair value for Spectral AI Inc. is $1.84 (as of Jun 23, 2026), built from audited fundamentals. The current price: $1.62.
What is the quality score of MDAI?
Spectral AI Inc. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Spectral AI Inc. (MDAI)?
Our model-based price target is the fair value of $1.84 (as of Jun 23, 2026) from 3 valuation models. Cautious scenario $1.38, optimistic scenario $2.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Spectral AI Inc. stock forecast for 2026?
Our models put fair value at $1.84, about +13% upside versus a price of $1.62 (undervalued). Cautious scenario $1.38, optimistic scenario $2.30. The calculation is refreshed regularly with new filings.
What is the revenue of Spectral AI Inc. (MDAI)?
Spectral AI Inc. reported trailing-twelve-month revenue of about $15.4M (latest available figure, as of Jun 23, 2026).
What is the intrinsic value of Spectral AI Inc. (MDAI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Spectral AI Inc. it is $1.84 per share (as of Jun 23, 2026), against a price of $1.62. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Spectral AI Inc. stock overvalued or undervalued in 2026?
As of Jun 23, 2026, MDAI trades below its calculated fair value: price $1.62, fair value $1.84, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDAI?
No. The price is what the market pays today ($1.62); the fair value is what the company's own numbers justify ($1.84). For Spectral AI Inc. the two are $0.2160 per share apart. That gap is exactly why we show both numbers side by side.
How much is Spectral AI Inc. worth?
The market values Spectral AI Inc. at about $52.0M (market capitalisation, as of Jun 23, 2026). Per share that is $1.62; our models calculate a fair value of $1.84 per share.
What do the bullish and bearish scenarios say about MDAI?
Our models span a range for Spectral AI Inc.: cautious scenario $1.38, base $1.84, optimistic $2.30 per share (as of Jun 23, 2026, price $1.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Spectral AI Inc. (MDAI)?
Balance-sheet figures for Spectral AI Inc. (as of Jun 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is MDAI from its 52-week high?
Spectral AI Inc. trades at $1.62, about 40% below its 52-week high of $2.68 and 35% above the low of $1.20 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $1.84 is for.
Which stocks are comparable to Spectral AI Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Spectral AI Inc. stock attractive at the current price?
The data as of Jun 23, 2026: price $1.62, calculated fair value $1.84 (+13%), Quality Score 37/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDAI calculated?
We run Spectral AI Inc. through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.84, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Spectral AI Inc. currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Spectral AI Inc. (MDAI)?
The closing price on Sep 24, 2026 was $1.62. Our model-based fair value is $1.84, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Spectral AI Inc. right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Spectral AI Inc.

How large is the market capitalisation of Spectral AI Inc. (MDAI)?
The market capitalisation of Spectral AI Inc. is $52.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Spectral AI Inc. (MDAI)?
The price-to-sales ratio of Spectral AI Inc. is 3.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Spectral AI Inc. (MDAI)?
Earnings per share at Spectral AI Inc. are $−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Spectral AI Inc. (MDAI)?
The net margin of Spectral AI Inc. is −38.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Spectral AI Inc. (MDAI)?
The return on equity (ROE) of Spectral AI Inc. is −2,308% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Spectral AI Inc. (MDAI)?
On an EBIT basis the return on assets of Spectral AI Inc. is −50.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Spectral AI Inc. (MDAI)?
The operating margin of Spectral AI Inc. is −123% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Spectral AI Inc. (MDAI)?
Revenue at Spectral AI Inc. is growing −30.4% versus a year earlier (3y avg −8.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Spectral AI Inc. (MDAI) generate?
The free cash flow of Spectral AI Inc. is −$9.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Spectral AI Inc. (MDAI) hold?
Spectral AI Inc. holds more cash than debt, $5.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Spectral AI Inc. in the live analysis

One click puts Spectral AI Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.